|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1987; 10:998-1006 © 1987 by the American College of Cardiology Foundation |
Abteilung fur Kardiologie, Universitatskrankenhaus Eppendorf, Hamburg, West Germany.
Thromboxane released from activated platelets and prostacyclin of the vessel wall may act as potent antagonistic modulators of platelet aggregability and coronary vascular tone. Therefore, urinary excretion of their major metabolites, 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1 alpha, was studied in 16 patients presenting with prolonged angina at rest. The 10 patients whose condition did not improve under vigorous antianginal treatment within 48 hours exhibited higher thromboxane metabolite excretion than did the 6 patients who responded to therapy (2,208 +/- 1,542 versus 609 +/- 312 ng/g creatinine; p less than 0.001). Elevated values were also found in four of eight patients with sustained postinfarction angina. Enhanced thromboxane metabolite excretion was frequently associated with angiographic evidence of thrombus formation. When nine patients were restudied in a stable phase after 11 +/- 5 months, thromboxane metabolite excretion was consistently normal or high normal. Excretion of prostacyclin metabolites was not depressed in any patient but correlated weakly with thromboxane (r = 0.41). Thus, enhanced thromboxane production as an index of platelet activation may identify patients with active thrombus formation who could benefit most from platelet inhibitory treatment.
This article has been cited by other articles:
|
|
 |
|
  D. J. Duncker and R. J. Bache Regulation of Coronary Blood Flow During Exercise Physiol Rev, July 1, 2008; 88(3): 1009 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Dogne, J. Hanson, X. de Leval, P. Kolh, V. Tchana-Sato, L. de Leval, S. Rolin, A. Ghuysen, P. Segers, B. Lambermont, et al. Pharmacological Characterization of N-tert-Butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a Novel Thromboxane A2 Receptor Antagonist and Thromboxane Synthase Inhibitor in a Rat Model of Arterial Thrombosis and Its Effects on Bleeding Time J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 498 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mousa, J. M. Bozarth, M. S. Forsythe, and A. Slee Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels Cardiovasc Res, September 1, 2000; 47(4): 819 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mousa, S. Khurana, and M. S. Forsythe Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography : Differentiation Among Glycoprotein IIb/IIIa Antagonists Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1162 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Neufeld, U. Nowak-Gottl, and R. Junker Citrate-Theophylline-Adenine-Dipyridamol Buffer Is Preferable to Citrate Buffer as an Anticoagulant for Flow Cytometric Measurement of Platelet Activation Clin. Chem., November 1, 1999; 45(11): 2030 - 2033. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gawaz, F.-J. Neumann, and A. Schomig Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy Circulation, January 12, 1999; 99 (1): e1 - e11. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Zaacks, P. R. Liebson, J. E. Calvin, J. E. Parrillo, and L. W. Klein Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J. Am. Coll. Cardiol., January 1, 1999; 33(1): 107 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mousa, J. M. Bozarth, W. Lorelli, M. S. Forsythe, M. J. M. C. Thoolen, A. M. Slee, T. M. Reilly, and P. A. Friedman Antiplatelet Efficacy of XV459, A Novel Nonpeptide Platelet GPIIb/IIIa Antagonist: Comparative Platelet Binding Profiles with c7E3 J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1277 - 1284. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Bednar, S. L. Gaul, T. G. Hamill, M. S. Egbertson, J. A. Shafer, G. D. Hartman, R. J. Gould, and B. Bednar Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1317 - 1326. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. A. Mousa, D.-X. Mu, and B. R. Lucchesi Prevention of Carotid Artery Thrombosis by Oral Platelet GPIIb/IIIa Antagonist in Dogs Stroke, April 1, 1997; 28(4): 830 - 836. [Abstract] [Full Text]
|
|
|
|
|
|
I. Ott, F.-J. Neumann, M. Gawaz, M. Schmitt, and A. Schomig Increased Neutrophil-Platelet Adhesion in Patients With Unstable Angina Circulation, September 15, 1996; 94(6): 1239 - 1246. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Mousa, W. F. DeGrado, D.-X. Mu, R. P. Kapil, B. R. Lucchesi, and T. M. Reilly Oral Antiplatelet, Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Antagonist Circulation, February 1, 1996; 93(3): 537 - 543. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. E. Kjeldsen, A. B. Weder, B. Egan, R. Neubig, A. J. Zweifler, and S. Julius Effect of Circulating Epinephrine on Platelet Function and Hematocrit Hypertension, May 1, 1995; 25(5): 1096 - 1105. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Patrono Aspirin as an Antiplatelet Drug N. Engl. J. Med., May 5, 1994; 330(18): 1287 - 1294. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
